TMCnet News
Codiak BioSciences Expands Executive Leadership– Sriram Sathyanarayanan, Ph.D. promoted to Chief Scientific Officer – – Konstantin Konstantinov, Ph.D. named Chief Technology Officer – CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the promotion of Sriram Sathyanarayanan, Ph.D., who has led Codiak’s preclinical research efforts for the past four years to Chief Scientific Officer. Additionally, Konstantin Konstantinov, Ph.D., who has spearheaded the company’s manufacturing and process sciences since Codiak’s inception, has been named Chief Technology Officer. “Both Sriram and Konstantin are highly-regarded experts in their respective fields and have been instrumental in the realization of our exosome engineering platform and our significant progress as a company to date,” said Douglas E. Williams, Ph.D., CEO, Codiak. “As the architect of our lead R&D programs, Sriram is currently driving the research innovation critical to cultivating the next generation of our pipeline. With his background in oncology and immuno-oncology, he has skillfully guided two of our exosome therapeutic candidates to the clinic and a third toward IND. Konstantin’s work to build – from the ground up – a robust and reproducible exosome manufacturing process capable of producing scalable, GMP-grade therapeutics forms the backbone of our entire engEx™ platform and is setting new standards for our industry. I am delighted to work alongside these long-time colleagues as we chart the path for Codiak's next phase of growth.” Prior to this appointment, Dr. Sathyanarayanan was Senior Vice President, Preclinical Development. In this role, he designed and led the preclinical evaluation of all of Codiak’s development programs in oncology/immuno-oncology, including exoIL-12™ and exoSTING™, which are currently in Phase 1/2 clinical trials, and exoASO™-STAT6, for which Codiak expects to file an Investigational New Drug application this year. Dr. Sathyanarayanan joined Codiak in 2017 as Vice President, Biology and Translational Sciences after spending four years developing biomarker strategies to enable clinical development of novel cancer immunotherapy agents, including JTX-2011 from inception to Phase 2 clinical developmet, at Jounce Therapeutics as Senior Director, Translational Sciences. He began his career in drug discovery at Merck Research Laboratories where he was responsible for building translational oncology strategy for multiple biologics and small molecules programs including Dalotuzumab and Ridaforolimus. Dr. Sathyanarayanan completed his post-doctoral research at the University of Pennsylvania School of Medicine. He received his Ph.D. in microbiology and cell biology from the Indian Institute of Science and masters and undergraduate degrees in biochemistry from PSG College. Dr. Konstantinov most recently held the position of Executive Vice President, Manufacturing and Process Sciences. Before joining Codiak in January 2016, he was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston hub, including all functions from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer-reviewed papers and has more than 15 patents and patent applications. Over the course of his career, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he forged the development of an end-to-end integrated continuous biomanufacturing platform, which led the way for a strategic technological shift in the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in biochemical engineering from Osaka University in Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware. Dr. Konstantinov is the recipient of many awards for his contributions to the field, including most recently the American Chemical Society and AIChE’s D.I.C. Wang Award for Excellence in Biochemical Engineering. About Codiak BioSciences Forward-Looking Statements Investor Contact: Christopher Taylor VP, Investor Relations and Corporate Communications T: 617-949-4220 E: [email protected] Media Contact: Lindy Devereux Scient PR T: 646-515-5730 E: [email protected] |